We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
-19.67%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$2.74B
AUM Growth
-$52.2M
Cap. Flow
+$616M
Cap. Flow %
22.46%
Top 10 Hldgs %
20.88%
Holding
327
New
27
Increased
203
Reduced
54
Closed
34

Top Buys

Rank Stock Value
1
MYGN icon
Myriad Genetics
MYGN
+$28.8M
2
WW
WW International
WW
+$26.6M
3
WIX icon
WIX.com
WIX
+$21.1M
4
PINC
Premier
PINC
+$20.4M
5
URBN icon
Urban Outfitters
URBN
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.84%
2 Industrials 19.01%
3 Technology 16.97%
4 Consumer Discretionary 11%
5 Communication Services 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VBK icon
251
Vanguard Morningstar Small-Cap Growth ETF
VBK
$24.6B
$865K 0.03%
+5,743
New +$947K
ABBV icon
252
AbbVie
ABBV
$435B
$856K 0.03%
9,282
-5,163
-36% -$454K
PNTR
253
DELISTED
Pointer Telocation Ltd.
PNTR
$843K 0.03%
69,384
+25,635
+59% +$308K
XOM icon
254
ExxonMobil
XOM
$634B
$816K 0.03%
11,971
+433
+4% +$34K
LHX icon
255
L3Harris
LHX
$53.4B
$815K 0.03%
6,056
MEET
256
DELISTED
The Meet Group, Inc. Common Stock
MEET
$785K 0.03%
169,639
+61,983
+58% +$264K
CSW
257
CSW Industrials
CSW
$5.71B
$778K 0.03%
16,087
+5,853
+57% +$291K
DIS icon
258
Walt Disney
DIS
$181B
$762K 0.03%
6,950
-2,937
-30% -$334K
ABT icon
259
Abbott
ABT
$187B
$718K 0.03%
9,924
-5,163
-34% -$363K
CVX icon
260
Chevron
CVX
$366B
$704K 0.03%
6,467
+392
+6% +$45.4K
RVNC
261
DELISTED
Revance Therapeutics, Inc.
RVNC
$668K 0.02%
33,193
+8,821
+36% +$194K
LIND icon
262
Lindblad Expeditions
LIND
$2.22B
$647K 0.02%
48,046
+13,490
+39% +$180K
MRK icon
263
Merck
MRK
$318B
$617K 0.02%
8,456
+401
+5% +$28.3K
PEP icon
264
PepsiCo
PEP
$190B
$526K 0.02%
4,765
-6,682
-58% -$753K
COHR icon
265
Coherent
COHR
$74.2B
$489K 0.02%
15,068
-327,267
-96% -$12.2M
NVCR icon
266
NovoCure
NVCR
$1.91B
$489K 0.02%
14,615
-72
-0.5% -$2.63K
WMT icon
267
Walmart Inc
WMT
$890B
$489K 0.02%
15,750
-300
-2% -$9.62K
J icon
268
Jacobs Solutions
J
$17B
$482K 0.02%
9,962
-12,513
-56% -$715K
MCO icon
269
Moody's
MCO
$82.7B
$467K 0.02%
3,336
+317
+11% +$47.8K
NVRO
270
DELISTED
NEVRO CORP.
NVRO
$421K 0.02%
+10,823
New +$481K
TXMD icon
271
TherapeuticsMD
TXMD
$24M
$392K 0.01%
+2,057
New +$502K
PG icon
272
Procter & Gamble
PG
$339B
$353K 0.01%
3,844
+1,205
+46% +$108K
TRUE
273
DELISTED
TrueCar
TRUE
$350K 0.01%
38,663
+14,074
+57% +$152K
INTC icon
274
Intel
INTC
$513B
$333K 0.01%
7,100
-900
-11% -$42.1K
CAG icon
275
Conagra Brands
CAG
$7.23B
$326K 0.01%
+15,281
New +$494K

Similar funds

Rice Hall James & Associates's Q4 2018 Portfolio in Review

As of Q4 2018, Rice Hall James & Associates held 327 positions worth $2.74B, down 1.9% from $2.79B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Rice Hall James & Associates deployed $616M of net new capital in Q4 2018, opening 27 new positions and adding to 203 existing holdings. Its largest new stake was Myriad Genetics: 800,553 shares worth $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 22% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Coherent, an estimated $12.2M trimmed.

  • Rice Hall James & Associates's largest Q4 2018 buy was Myriad Genetics: 800,553 shares worth $23.3M.
  • Rice Hall James & Associates added most to WW International in Q4 2018, an estimated $26.6M increase.
  • Rice Hall James & Associates's biggest Q4 2018 reduction was Coherent, cutting an estimated $12.2M.
  • Rice Hall James & Associates fully exited Conduent in Q4 2018, selling an estimated $25.1M.
  • Rice Hall James & Associates's ten largest holdings make up 21% of its $2.74B portfolio in Q4 2018.
  • Rice Hall James & Associates opened 27 new positions and closed 34 in Q4 2018.
  • Rice Hall James & Associates's portfolio value fell 1.9% quarter-over-quarter to $2.74B.

Based on Rice Hall James & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.